By Editor , 11 September 2026

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a class action lawsuit against Blaize Holdings, Inc. (NASDAQ: BZAI), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit covers investors who purchased BZAI shares between July 18, 2025 and April 28, 2026, with a lead plaintiff filing deadline set for October 5, 2026.

By Editor , 11 September 2026

Los Angeles – September 10, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff filing deadline set for November 3, 2026.

By Editor , 11 September 2026

Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.

By Editor , 11 September 2026
ATTACK SHARK Signs Gear Partnership With Cloud9 Esports

New York – September 10, 2026 -- Gaming peripherals brand ATTACK SHARK has struck a partnership with Cloud9 Esports, one of North America's most decorated e-sports organizations, to equip its League of Legends roster with hardware for daily training and competition prep.

By Editor , 11 September 2026

Los Angeles – September 10, 2026 -- DJS Law Group has issued a reminder to investors of a securities class action lawsuit against GPGI, Inc., formerly known as CompoSecure, Inc. (NYSE: GPGI), with a lead plaintiff deadline set for September 15, 2026.

By Editor , 11 September 2026
Regeneron Sued Over Failed Melanoma Trial, $11B Market Cap Loss

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.

By Editor , 11 September 2026
PROCEPT BioRobotics Hit With Securities Suit Over Handpiece Sales

San Francisco – September 10, 2026 -- A securities class action has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging the company inflated handpiece sales through an undisclosed bulk-discount program that pulled forward demand and masked deteriorating customer inventory levels. Law firm Hagens Berman Sobol Shapiro LLP is representing investors who purchased PROCEPT stock between February 28, 2024 and February 25, 2026, with a lead plaintiff deadline set for September 22, 2026.

By Editor , 11 September 2026
Cogent Communications Hit With Securities Suit Over Wavelength Backlog

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Cogent Communications Holdings (NASDAQ: CCOI), alleging the company misrepresented its optical wavelength "backlog" as a reliable indicator of revenue growth between February 29, 2024 and May 1, 2026.

By Editor , 11 September 2026
Wix Faces Securities Suit After AI Costs Erase $1.1B in Market Value

San Francisco – September 10, 2026 -- Wix.com Ltd. (NASDAQ: WIX) is now the target of a securities class action following a 27% plunge in its share price after the company disclosed Q1 2026 results showing operating expenses had spiked 46% year-over-year. The case, Yappi v. Wix.com Ltd., et al., No. 26-cv-08852, was filed in the U.S. District Court for the Northern District of Illinois and seeks to represent investors who bought Wix securities between February 19, 2025 and May 12, 2026.

By Editor , 11 September 2026
Capricor Investors Face Sept. 28 Deadline as FDA Delays Deramiocel Ruling

San Francisco – September 10, 2026 -- Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have until September 28, 2026, to seek lead plaintiff status in a securities class action tied to the company's Duchenne muscular dystrophy therapy, deramiocel, as the FDA extends its review timeline.